Swedish Firm Bets on Doctor-Recommended Supplements to Disrupt US Blood Sugar Market

NEW YORK, NY – November 03, 2025 – Sigrid Therapeutics, a Swedish consumer care company, is making a bold move in the competitive U.S. supplement market. Traditionally selling directly to consumers, the company is now pivoting to a business-to-business (B2B) model, focusing on recommendations and distribution through healthcare professionals. This strategic shift centers on its ‘Glucose Stabiliser,’ a dietary supplement formulated with a patented silica particle technology, SiPore®, designed to manage blood sugar levels.

Prescription Supplements: A Growing Trend?

The rise of supplements recommended – and even sold – directly by doctors is gaining momentum. While traditionally the realm of pharmaceutical drugs, a growing number of healthcare practitioners are incorporating supplements into their treatment plans, particularly in areas like metabolic health and preventative care. This trend is fueled by patient demand for natural and holistic approaches to wellness, alongside a growing body of research supporting the efficacy of certain supplements.

“We’re seeing a definite shift in how practitioners view supplements,” says one anonymous physician specializing in functional medicine. “Patients are increasingly proactive about their health, and they’re asking about non-pharmaceutical options. When we can recommend a product with solid clinical backing, it becomes a valuable part of a comprehensive treatment plan.”

Sigrid’s move is capitalizing on this shift, aiming to establish credibility by partnering with physicians and positioning its ‘Glucose Stabiliser’ as a clinically-supported solution for blood sugar management. The company’s classification as a “medical food” in the US, instead of a traditional dietary supplement, also reflects this strategy. “The medical food designation is crucial,” explains a regulatory expert. “It signals that this isn’t just another over-the-counter product; it's intended for dietary management of a specific condition and used under medical supervision.”

The Science Behind SiPore® and the Pursuit of Metabolic Health

At the heart of Sigrid’s product is SiPore® technology. These are microscopic, porous silica particles engineered to interact with food in the gut. The company claims these particles slow down the digestion of carbohydrates and fats, resulting in a more gradual release of glucose into the bloodstream. This mechanism, they say, helps maintain stable blood sugar levels, which is crucial for energy, weight management, and preventing chronic diseases.

“Maintaining stable blood sugar is about more than just avoiding diabetes,” explains a nutrition scientist. “Fluctuations in blood sugar can lead to energy crashes, cravings, and increased risk of inflammation. Supporting consistent glucose levels is essential for overall metabolic health.”

The company's claims are supported by a growing body of clinical research. Sigrid cites six clinical trials demonstrating the efficacy of SiPore® technology, including a recently completed trial (SHINE - NCT06087822) investigating its performance in individuals with prediabetes. The company also holds numerous patents globally protecting its SiPore® technology, including US patents US 12,121,612 and US 10,695,294.

However, the supplement market is increasingly crowded, and competition is fierce. The global glucose management supplements market is projected to reach US$15.4 billion by 2032, with major players already vying for market share. “Consumers are bombarded with options,” says an industry analyst. “Standing out requires more than just good science; it requires a strong brand, effective marketing, and a clear value proposition.”

Navigating a Competitive Landscape and Looking Ahead

Sigrid’s decision to focus on physician recommendations is a strategic attempt to differentiate itself from the competition. By partnering with healthcare professionals, the company hopes to build trust and credibility, particularly among health-conscious consumers seeking evidence-based solutions. This also allows the company to potentially bypass some of the challenges associated with direct-to-consumer marketing, such as high advertising costs and increasing regulatory scrutiny.

The company's pilot program, conducted with integrative and functional medicine clinics, appears to be a key component of this strategy. While details regarding the performance of the pilot program are limited, the company reports positive results and plans to expand its reach to a wider network of healthcare providers.

However, success will depend on several factors, including the company’s ability to effectively educate physicians about SiPore® technology, build strong relationships with key opinion leaders, and demonstrate the long-term benefits of its product. “The physician channel is competitive,” says one anonymous healthcare executive. “Getting doctors to consistently recommend your product requires a sustained effort and a compelling value proposition.”

The rise of GLP-1 medications for diabetes and weight management also presents both challenges and opportunities. While these drugs are highly effective, they also require ongoing medical supervision and can have side effects. Supplements like Sigrid’s ‘Glucose Stabiliser’ may appeal to individuals seeking a more natural and holistic approach to metabolic health, or as a complementary therapy alongside conventional treatments.